This site will be undergoing maintenance on Friday, July 21, 2017 from 9:00 pm to 3:30 am EST Saturday, July 22.
During this time Login and Request Quote functionality will be temporarily unavailable.
As a brand of Thermo Fisher Scientific, our commitment is to provide the most consistent and reliable reagents. The driving force behind our product development and educational programs is facilitating a new standard of care in transplant monitoring. We develop and distribute a comprehensive line of HLA typing and antibody detection products, laboratory instrumentation, and computer software that are used to simplify and automate testing procedures and final test evaluations. Our diagnostic tests are used by transplant centers worldwide to determine the compatibility of donors and recipients pre-transplant, and post-transplant to detect the presence of antibodies that can lead to transplant rejection.
One Lambda was founded in 1984 by Dr. Paul Terasaki, a pre-eminent researcher in the field of transplantation. From its inception, the company has been at the forefront of transplant diagnostics and has been first to market with a number of cutting edge solutions that have helped laboratories and clinicians meet the ever increasing demands for high quality data and improved patient outcomes.
In July of 2012, One Lambda was acquired by Thermo Fisher Scientific, the world leader in serving science. Thermo Fisher Scientific’s global presence and extensive customer channel network have enhanced our ability to deliver our products and services to HLA laboratories worldwide. We remain committed to improving the quality of life of transplant patients and their families by developing and producing innovative, high quality HLA products for the clinical and research segments of the transplant community.
The future is an opportunity to apply the traditions of quality and innovation to rapidly advancing technology. With a core market firmly established, we look beyond the familiar, researching ways to touch not only histocompatibility, but all of transplantation.
Our policy is to maintain compliance with all applicable worldwide regulations while consistently delivering quality products and services that will meet and /or anticipate the needs of the global scientific and transplant communities.
The implementation of a pro-active quality management system based on continuous process improvement will ensure that quality is the fundamental value that is "built" into every process and product.